Pneumocystis pneumonia among patients with systemic diseases;Pneumocystose au cours des maladies systémiques

Presse Medicale

Volumn 38, Issue 2, 2009, Pages 251-259

  Khellaf, Mehdi ^a   Godeau, Bertrand ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PREDNISONE;

ARTIFICIAL VENTILATION; CLINICAL FEATURE; DELAYED DIAGNOSIS; DIAGNOSTIC IMAGING; HUMAN; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; LYMPHOCYTOPENIA; MALNUTRITION; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; RHEUMATIC DISEASE; RISK ASSESSMENT; SENESCENCE; SHORT SURVEY; SYSTEMIC DISEASE; TREATMENT DURATION; WEGENER GRANULOMATOSIS;

ADRENAL CORTEX HORMONES; ARTHRITIS, RHEUMATOID; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; OPPORTUNISTIC INFECTIONS; PNEUMONIA, PNEUMOCYSTIS; PREDNISONE; RHEUMATIC DISEASES; WEGENER GRANULOMATOSIS;

EID: 58649100666     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2008.11.004     Document Type: Short Survey

References (55)

1. Stringer J.R., Beard C.B., Miller R.F., and Wakefield A.E. A new name (Pneumocystis jiroveci) for pneumocystis from humans. Emerg Infect Dis 8 (2002) 891-896
2. Chave J.P., David S., Wauters J.P., Van Melle G., and Francioli P. Transmission of Pneumocystis carinii from AIDS patients to other immunosuppressed patients: a cluster of pneumocystis carinii pneumonia in renal transplant recipients. Aids 5 (1991) 27-32
3. Arend S.M., Kroon F.P., and van't Wout J.W. Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993. An analysis of 78 cases. Arch Intern Med 155 (1995) 2436-2441
4. Yale S.H., and Limper A.H. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 71 (1996) 5-13
5. Ward M.M., and Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum 42 (1999) 780-789
6. Godeau B., Coutant-Perronne V., Le Thi Huong D., Guillevin L., Magadur G., De Bandt M., et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol 21 (1994) 246-251
7. Ognibene F.P., Shelhamer J.H., Hoffman G.S., Kerr G.S., Reda D., Fauci A.S., et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am J Respir Crit Care Med 151 (1995) 795-799
8. Marie I., Hachulla E., Cherin P., Hellot M.F., Herson S., Levesque H., et al. Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum 53 (2005) 155-165
9. Liam C.K., and Wang F. Pneumocystis carinii pneumonia in patients with systemic lupus erythematosus. Lupus 1 (1992) 379-385
10. Rodriguez M., and Fishman J.A. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 17 (2004) 770-782
11. Sepkowitz K.A. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis 34 (2002) 1098-1107
12. Kovacs J.A., Hiemenz J.W., Macher A.M., Stover D., Murray H.W., Shelhamer J., et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 100 (1984) 663-671
13. Mansharamani N.G., Balachandran D., Vernovsky I., Garland R., and Koziel H. Peripheral blood CD4 + T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest 118 (2000) 712-720
14. Robberts F.J., Liebowitz L.D., and Chalkley L.J. Polymerase chain reaction detection of Pneumocystis jiroveci: evaluation of 9 assays. Diagn Microbiol Infect Dis 58 (2007) 385-392
15. Fillaux J., Malvy S., Alvarez M., Fabre R., Cassaing S., Marchou B., et al. Accuracy of a routine real-time PCR assay for the diagnosis of Pneumocystis jirovecii pneumonia. J Microbiol Methods 75 (2008) 258-261
16. Sowden E., and Carmichael A.J. Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention. BMC Infect Dis 4 (2004) 42
17. Iikuni N., Kitahama M., Ohta S., Okamoto H., Kamatani N., and Nishinarita M. Evaluation of pneumocystis pneumonia infection risk factors in patients with connective tissue disease. Mod Rheumatol 16 (2006) 282-288
18. Slivka A., Wen P.Y., Shea W.M., and Loeffler J.S. Pneumocystis carinii pneumonia during steroid taper in patients with primary brain tumors. Am J Med 94 (1993) 216-219
19. Stenger A.A., Houtman P.M., Bruyn G.A., Eggink H.F., and Pasma H.R. Pneumocystis carinii pneumonia associated with low dose methotrexate treatment for rheumatoid arthritis. Scand J Rheumatol 23 (1994) 51-53
20. Godeau B., Mainardi J.L., Roudot-Thoraval F., Hachulla E., Guillevin L., Huong Du L.T., et al. Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis. Ann Rheum Dis 54 (1995) 991-994
21. Martin S.I., Marty F.M., Fiumara K., Treon S.P., Gribben J.G., and Baden L.R. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 43 (2006) 16-24
22. Kaur N., and Mahl T.C. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci 52 (2007) 1481-1484
23. Enomoto T., Azuma A., Matsumoto A., Nei T., Fujita K., Hattori K., et al. Preventive effect of sulfamethoxasole-trimethoprim on Pneumocystis jiroveci pneumonia in patients with interstitial pneumonia. Intern Med 47 (2008) 15-20
24. Hughes W.T., Kuhn S., Chaudhary S., Feldman S., Verzosa M., Aur R.J., et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 297 (1977) 1419-1426
25. Green H., Paul M., Vidal L., and Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 82 (2007) 1052-1059
26. Colby C., McAfee S., Sackstein R., Finkelstein D., Fishman J., and Spitzer T. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 24 (1999) 897-902
27. Reinke C.M., Thomas J.K., and Graves A.H. Apparent hemolysis in an AIDS patient receiving trimethoprim/sulfamethoxazole: case report and literature review. J Pharm Technol 11 (1996) 256-262
28. Razavi B., Lund B., Allen B.L., and Schlesinger L. Failure of trimethoprim/sulfamethoxazole prophylaxis for Pneumocystis carinii pneumonia with concurrent leucovorin use. Infection 30 (2002) 41-42
29. Chevrel G., Brantus J.F., Sainte-Laudy J., and Miossec P. Allergic pancytopenia to trimethoprim-sulphamethoxazole for Pneumocystis carinii pneumonia following methotrexate treatment for rheumatoid arthritis. Rheumatology (Oxford) 38 (1999) 475-476
30. Thomas Jr. C.F., and Limper A.H. Pneumocystis pneumonia. N Engl J Med 350 (2004) 2487-2498
31. Langford C.A., Talar-Williams C., Barron K.S., and Sneller M.C. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 114 (2003) 463-469
32. Verdier R.I., Fitzgerald D.W., Johnson Jr. W.D., and Pape J.W. Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients. A randomized, controlled trial. Ann Intern Med 132 (2000) 885-888
33. Ioannidis J.P., Cappelleri J.C., Skolnik P.R., Lau J., and Sacks H.S. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med 156 (1996) 177-188
34. Jensen P.A., Lambert L.A., Iademarco M.F., and Ridzon R. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep 54 RR-17 (2005) 1-141
35. Fishman J.A. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis 33 (2001) 1397-1405
36. Jules-Elysee K.M., Stover D.E., Zaman M.B., Bernard E.M., and White D.A. Aerosolized pentamidine: effect on diagnosis and presentation of Pneumocystis carinii pneumonia. Ann Intern Med 112 (1990) 750-757
37. Torres R.A., Barr M., Thorn M., Gregory G., Kiely S., Chanin E., et al. Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. Am J Med 95 (1993) 573-583
38. Podzamczer D., Salazar A., Jimenez J., Consiglio E., Santin M., Casanova A., et al. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann Intern Med 122 (1995) 755-761
39. Chan C., Montaner J., Lefebvre E.A., Morey G., Dohn M., McIvor R.A., et al. Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. J Infect Dis 180 (1999) 369-376
40. Foot A.B., Garin Y.J., Ribaud P., Devergie A., Derouin F., and Gluckman E. Prophylaxis of toxoplasmosis infection with pyrimethamine/sulfadoxine (Fansidar) in bone marrow transplant recipients. Bone Marrow Transplant 14 (1994) 241-245
41. Ena J., Amador C., Pasquau F., Carbonell C., Benito C., Gutierrez F., et al. Once-a-month administration of intravenous pentamidine to patients infected with human immunodeficiency virus as prophylaxis for Pneumocystis carinii pneumonia. Clin Infect Dis 18 (1994) 901-904
42. Azevedo L.S., Castro M.C., Paula F.J., Ianhez L.E., and David-Neto E. Mycophenolate mofetil may protect against Pneumocystis carinii pneumonia in renal transplanted patients. Rev Inst Med Trop Sao Paulo 47 (2005) 143-145
43. Wells J., Haidaris C.G., Wright T.W., and Gigliotti F. Active immunization against Pneumocystis carinii with a recombinant P. carinii antigen. Infect Immun 74 (2006) 2446-2448
44. Chougule M., Padhi B., and Misra A. Development of spray dried liposomal dry powder inhaler of Dapsone. AAPS PharmSciTech 9 (2008) 47-53
45. Vasconcelles M.J., Bernardo M.V., King C., Weller E.A., and Antin J.H. Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biol Blood Marrow Transplant 6 (2000) 35-43
46. Kimura M., Tanaka S., Ishikawa A., Endo H., Hirohata S., and Kondo H. Comparison of trimethoprim-sulfamethoxazole and aerosolized pentamidine for primary prophylaxis of Pneumocystis jiroveci pneumonia in immunocompromised patients with connective tissue disease. Rheumatol Int 28 (2008) 673-676
47. Hashimoto H. Prophylaxis of Pneumocystis Jiroveci pneumonia in autoimmune disease (in japanese). Clinical Guideline. Tokyo:japanese ministry of health, labour and welfare study group on complication and treatment of immune disease. In: Hashimoto H, editor 2005: p. 14-9.
48. Wung P.K., and Stone J.H. Therapeutics of Wegener's granulomatosis. Nat Clin Pract Rheumatol 2 (2006) 192-200
49. Popa E.R., Stegeman C.A., Kallenberg C.G., and Tervaert J.W. Staphylococcus aureus and Wegener's granulomatosis. Arthritis Res 4 (2002) 77-79
50. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2007; 3:CD005590.
51. Gilliland W.R., and Tsokos G.C. Prophylactic use of antibiotics and immunisations in patients with SLE. Ann Rheum Dis 61 (2002) 191-192
52. Roblot F., Godet C., Le Moal G., Garo B., Faouzi-Souala M., Dary M., et al. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur J Clin Microbiol Infect Dis 21 (2002) 523-531
53. Dykewicz C.A. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 33 (2001) 139-144
54. Suryaprasad A., and Stone J.H. When is it safe to stop pneumocystis jiroveci pneumonia prophylaxis? insights from three cases complicating autoimmune diseases. Arthritis Rheum 59 (2008) 1034-1039
55. Meyers B., Borrego F., and Papanicolaou G. Pneumocystis carinii pneumonia prophylaxis with atovaquone in trimethoprim-sulfamethoxazole-intolerant orthotopic liver transplant patients: a preliminary study. Liver Transpl 7 (2001) 750-751